These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35373695)

  • 1. Patient preferences for topical psoriasis treatments: a discrete choice experiment.
    Hoelker S; Ninosu N; Buettner S; Peitsch WK; Schaarschmidt ML
    J Dermatolog Treat; 2022 Aug; 33(5):2595-2604. PubMed ID: 35373695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.
    Kromer C; Schaarschmidt ML; Schmieder A; Herr R; Goerdt S; Peitsch WK
    PLoS One; 2015; 10(6):e0129120. PubMed ID: 26058083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient preferences for psoriasis treatments: impact of treatment experience.
    Schaarschmidt ML; Umar N; Schmieder A; Terris DD; Goebeler M; Goerdt S; Peitsch WK
    J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):187-98. PubMed ID: 22225546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes.
    Schaarschmidt ML; Schmieder A; Umar N; Terris D; Goebeler M; Goerdt S; Peitsch WK
    Arch Dermatol; 2011 Nov; 147(11):1285-94. PubMed ID: 22106115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare).
    Schaarschmidt ML; Herr R; Gutknecht M; Wroblewska K; Gerdes S; Sticherling M; Augustin M; Peitsch WK
    Acta Derm Venereol; 2018 Feb; 98(2):200-205. PubMed ID: 29110022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments.
    Sain N; Willems D; Charokopou M; Hiligsmann M
    Curr Med Res Opin; 2020 Aug; 36(8):1257-1275. PubMed ID: 32468865
    [No Abstract]   [Full Text] [Related]  

  • 7. Patient Preferences in Topical Psoriasis Treatment.
    Curcio A; Kontzias C; Gorodokin B; Feldman S; Kircik L
    J Drugs Dermatol; 2023 Apr; 22(4):326-332. PubMed ID: 37026884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most.
    Schaarschmidt ML; Kromer D; Wellmann P; Peitsch WK; Kromer C
    J Dermatolog Treat; 2024 Dec; 35(1):2308682. PubMed ID: 38297480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.
    Schaarschmidt ML; Kromer C; Herr R; Schmieder A; Sonntag D; Goerdt S; Peitsch WK
    PLoS One; 2015; 10(12):e0144335. PubMed ID: 26633680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States.
    Feldman SR; Holmen Moeller A; Erntoft Idemyr ST; González JM
    J Health Econ Outcomes Res; 2017; 4(2):141-157. PubMed ID: 37661952
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient preferences for attributes of topical anti-psoriatic medicines.
    Vasconcelos V; Teixeira A; Almeida V; Teixeira M; Ramos S; Torres T; Sousa Lobo JM; Almeida IF
    J Dermatolog Treat; 2019 Nov; 30(7):659-663. PubMed ID: 30470146
    [No Abstract]   [Full Text] [Related]  

  • 12. Psoriasis patient preferences for topical drugs: a systematic review.
    Svendsen MT; Feldman SR; Tiedemann SN; Sørensen ASS; Rivas CMR; Andersen KE
    J Dermatolog Treat; 2021 Aug; 32(5):478-483. PubMed ID: 31610687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.
    Hong CH; Papp KA; Lophaven KW; Skallerup P; Philipp S
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1876-1883. PubMed ID: 28796913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis patient preferences for the use of biologics during the coronavirus era.
    Tada Y; Itakura A; Hosono K; Kawamura T
    J Dermatol; 2023 May; 50(5):596-607. PubMed ID: 36628542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment burden and the perspectives of patients with psoriasis using topical treatments: results from a national survey of adults with psoriasis in the United States.
    Armstrong A; Young M; Seal MS; Higham RC; Greiling T
    J Dermatolog Treat; 2024 Dec; 35(1):2389174. PubMed ID: 39128848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan.
    Komine M; Kim H; Yi J; Zhong Y; Sakai Y; Crawford B; Habiro K; Hikichi Y; Feldman SR
    J Dermatol; 2023 Jun; 50(6):766-777. PubMed ID: 36808765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study.
    Boeri M; Saure D; Schuster C; Hill J; Guerreiro M; Klein K; Hauber B
    J Dermatolog Treat; 2022 May; 33(3):1598-1605. PubMed ID: 33406942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient preference for biologic treatments of psoriasis in Japan.
    Tada Y; Ishii K; Kimura J; Hanada K; Kawaguchi I
    J Dermatol; 2019 Jun; 46(6):466-477. PubMed ID: 30985030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.
    Kromer C; Peitsch WK; Herr R; Schmieder A; Sonntag D; Schaarschmidt ML
    J Dtsch Dermatol Ges; 2017 Feb; 15(2):189-200. PubMed ID: 28214326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comorbidities significantly impact patients' preferences for psoriasis treatments.
    Schmieder A; Schaarschmidt ML; Umar N; Terris DD; Goebeler M; Goerdt S; Peitsch WK
    J Am Acad Dermatol; 2012 Sep; 67(3):363-72. PubMed ID: 22015150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.